What the research actually shows
A series of large observational studies published in 2025-2026 have consistently found that people with type 2 diabetes treated with GLP-1 receptor agonists show significantly lower rates of Alzheimer's disease and other dementias compared to those treated with other glucose-lowering medications.
The most-cited study, a retrospective cohort analysis of over 1.6 million patients, found semaglutide users had a 40-70% lower incidence of new Alzheimer's diagnoses over a 3-year follow-up period. Liraglutide showed similar but somewhat smaller effects.
"These findings are striking, but we must be clear, observational data cannot prove causation. People who receive GLP-1 drugs may differ from comparison groups in important ways we cannot fully control for.", Lead author, University of Oxford, 2025
How GLP-1 drugs may protect the brain
GLP-1 receptors are widely expressed in the central nervous system, particularly in the hippocampus, cortex, and hypothalamus, regions critical to memory and cognition. Several mechanisms have been proposed:
- Neuroinflammation reduction: GLP-1 agonists suppress microglial activation and pro-inflammatory cytokine production, both implicated in Alzheimer's pathology.
- Improved cerebral insulin signalling: Alzheimer's has been described as "type 3 diabetes", a state of brain insulin resistance. GLP-1 drugs enhance neuronal insulin sensitivity.
- Amyloid and tau modulation: Animal and early human studies suggest reduced amyloid-beta plaque formation and tau phosphorylation with GLP-1 treatment.
- Neurogenesis promotion: GLP-1 appears to promote hippocampal neurogenesis and synaptic plasticity in preclinical models.
- Cardiovascular risk reduction: GLP-1 drugs significantly reduce stroke and cardiovascular events, both established risk factors for vascular dementia.
The critical caveats every patient should know
The headlines have been dramatic. The reality is more nuanced:
- No drug is approved for dementia prevention. These are off-label observations, not approved indications.
- The studies were in diabetic populations. Whether the same effects occur in people without diabetes is unknown.
- Randomised controlled trial data is pending. The EVOKE trial and HEAL trial are expected to report by 2027. These are the studies that will, or will not, confirm the observational findings.
- Significant side effects exist. Nausea, vomiting, gastroparesis risk, and rare cases of pancreatitis require careful patient selection and monitoring.
- Supply remains constrained. Prescribing for unapproved indications where supply is limited raises ethical and access concerns.
Current eligibility criteria for GLP-1 treatment
In the UK and most international guidelines, GLP-1 receptor agonists are currently approved for:
| Indication | Criteria | Example drugs |
|---|---|---|
| Type 2 diabetes | Inadequate glycaemic control on other agents | Semaglutide, liraglutide, dulaglutide |
| Obesity | BMI ≥30, or ≥27 with comorbidity | Semaglutide (Wegovy), liraglutide (Saxenda) |
| Cardiovascular risk reduction | Established CVD with T2DM | Semaglutide, liraglutide |
Dementia prevention is not a current approved indication in any country. Clinicians prescribing for this purpose would be doing so off-label with significant uncertainty about benefit-risk balance.
What this means for your clinical practice
For primary care clinicians and endocrinologists, the immediate practical message is straightforward: if a patient with type 2 diabetes or obesity meets criteria for GLP-1 treatment, the emerging neurological data is one more reason to consider it, not to withhold it while waiting for RCT confirmation.
For patients asking about GLP-1 drugs specifically for dementia prevention: be honest that the evidence is promising but preliminary. Lifestyle modification, exercise, sleep, Mediterranean diet, blood pressure control, has substantially stronger evidence for dementia risk reduction than any drug currently available.
Use our BMI Calculator to assess eligibility thresholds, and screen for comorbid depression, which is both a dementia risk factor and commonly undertreated in patients on GLP-1 therapy, with our PHQ-9 Depression Screening tool.
Frequently Asked Questions
References
- Wang W, et al. "Semaglutide and risk of Alzheimer's disease." Alzheimer's & Dementia. 2025.
- Atri A, et al. "GLP-1 receptor agonists and cognitive outcomes: systematic review." NEJM Evidence. 2026.
- Holscher C. "GLP-1 receptor agonists: A novel treatment approach in Alzheimer's disease." Brain Research. 2020;1725:146490.
- NICE. Semaglutide for managing overweight and obesity (TA875). NICE, 2023.